Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin in Early Huntington's Disease
NCT02453061Phase 2Completed
- Sponsor
- Inserm
- Start
- Jun 2015
- Primary completion
- Dec 2019
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing Placebo group with Triheptanoin group (2 arms). Primary endpoint: Volumetric Magnetic Resonance Imaging at 6 months. Started Jun 2015; status: completed.
02
Drugs
triheptanoin
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT02453061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453061.